Références

[2] CardioBrief: FDA's Gottlieb Preparing To Lower The Bar To Approval 2017. Available at: https://www.medpagetoday.com/cardiology/cardiobrief/68224 Accessed November 15, 2021.

[3] Nikolaidis GF, Woods B, Palmer S, et al. Classifying information-sharing methods. BMC Med Res Methodol 2021;21:107 10.1186/s12874-021-01292-z [34022810]

[4] Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996;15:2733–49 10.1002/(SICI)1097-0258(19961230)15:24<2733:AID-SIM562>3.0.CO 2-0; [8981683]

[5] Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med 2017;377:62–70 10.1056/NEJMra1510062 [28679092]

[6] Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ 2021;374:n1959 10.1136/bmj.n1959 [34497044]

[7] Hilal T, Gonzalez-Velez M, Prasad V. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2020;180:1108–15 10.1001/jamainternmed.2020.2250 [32539071]

[8] Hilal T, Sonbol MB, Prasad V. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncol 2019;5:887–92 10.1001/jamaoncol.2019.0167 [31046071]

[9] Naci H, Davis C, Savović J, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ 2019;366:l5221 10.1136/bmj.l5221 [31533922]

[10] Ladanie A, Schmitt AM, Speich B, et al. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Netw Open 2020;3:e2024406 10.1001/jamanetworkopen.2020.24406 [33170262]

[11] Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Internal Medicine 2015;175:1992–94 10.1001/jamainternmed.2015.5868 [26502403]

[12] Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine 2019;179:906–13 10.1001/jamainternmed.2019.0462 [31135808]

[13] BEECHER HK. Surgery as placebo. A quantitative study of bias. JAMA 1961;176:1102–07 10.1001/jama.1961.63040260007008 [13688614]

[14] Cohen PJ. Failure to conduct a placebo-controlled trial may be unethical. Am J Bioeth 2002;2:24 10.1162/152651602317533604 [12189067]

[15] Heckerling PS. The Ethics of Single Blind Trials. IRB: Ethics and Human Research 2005;27:12 10.2307/3563956

[16] Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. JAMA 2019;322:813–14 10.1001/jama.2019.9892 [31343666]

[17] Hwang TJ, Ross JS, Vokinger KN, et al. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 2020;371:m3434 10.1136/bmj.m3434 [33028575]

[18] Schnog J-JB, Samson MJ, Gans ROB, et al. An urgent call to raise the bar in oncology. Br J Cancer 2021 10.1038/s41416-021-01495-7 [34400802]

[19] Tannock IF, Amir E, Booth CM, et al. Relevance of randomised controlled trials in oncology. The Lancet Oncology 2016;17:e560-e567 10.1016/S1470-2045(16)30572-1 [27924754]

[20] Tannock IF, Templeton AJ. Flawed trials for cancer. Annals of Oncology 2020;31:331–33 10.1016/j.annonc.2019.11.017 [32067676]

[21] Cohen D. Cancer drugs: high price, uncertain value. BMJ 2017;359:j4543 10.1136/bmj.j4543 [28978508]

[22] Sachs RE, Gavulic KA, Donohue JM, et al. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval. JAMA Health Forum 2021;2:e213177 10.1001/jamahealthforum.2021.3177